Search Publications

Search Journals

Search Keywords

• Combined PD-1, BRAF and MEK inhibition in BRAF^V600E colorectal cancer: a phase 2 trial.

  Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen JN, Abrams TA, Clark JW, Enzinger AC, Enzinger PC, Klempner SJ, McCleary NJ, Meyerhardt JA, Ryan DP, Yurgelun MB, Kanter K, Van Seventer EE, Baiev I, Chi G, Jarnagin J, Bradford WB, Wong E, Michel AG, Fetter IJ, Siravegna G, Gemma AJ, Sharpe A, Demehri S, Leary R, Campbell CD, Yilmaz O, Getz GA, Parikh AR, Hacohen N, Corcoran RB.
  Nat Med. 2023 Jan 26. ().
  
  Clinical Trial

• Metabolism and Colorectal Cancer.

  Sedlak JC, Yilmaz ÖH, Roper J.
  Annu Rev Pathol. 2023 Jan 24. (18).

• BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8⁺ T cells.

  Romine KA, MacPherson K, Cho HJ, Kosaka Y, Flynn PA, Byrd KH, Coy JL, Newman MT, Pandita R, Loo CP, Scott J, Adey AC, Lind EF.
  Leukemia. 2023 Jan 21. ().

• Inhibition of SHP2 as an approach to block RAS-driven cancers.

  Chou YT, Bivona TG.
  Adv Cancer Res. 2022. (153).

• GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma.

  Morales J, Allegakoen DV, Garcia JA, Kwong K, Sahu PK, Fajardo DA, Pan Y, Horlbeck MA, Weissman JS, Gustafson WC, Bivona TG, Sabnis AJ.
  JCI Insight. 2022 Dec 08. 23(7).

• Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.

  Poulikakos PI, Sullivan RJ, Yaeger R.
  Clin Cancer Res. 2022 Nov 01. 21(28).

• Targeting colorectal cancer with small-molecule inhibitors of ALDH1B1.

  Feng Z, Hom ME, Bearrood TE, Rosenthal ZC, Fernández D, Ondrus AE, Gu Y, McCormick AK, Tomaske MG, Marshall CR, Kline T, Chen CH, Mochly-Rosen D, Kuo CJ, Chen JK.
  Nat Chem Biol. 2022 Oct. 10(18).

• Immune organoids: from tumor modeling to precision oncology.

  Dao V, Yuki K, Lo YH, Nakano M, Kuo CJ.
  Trends Cancer. 2022 Oct. 10(8).

• Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.

  Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ.
  Nat Commun. 2022 Sep 15. 1(13).

• Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling.

  Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, Gopalan A, Choo ZN, Persad S, Choi J, LaClair J, Lawrence KE, Chaudhary O, Xu T, Masilionis I, Linkov I, Wang S, Lee C, Barlas A, Morris MJ, Mazutis L, Chaligne R, Chen Y, Goodrich DW, Karthaus WR, Pe'er D, Sawyers CL.
  Science. 2022 Sep 09. 6611(377).

• Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.

  Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblentz C, Cohen AM, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Dibb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Monteblanco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, Spurgeon SE, Sweeney T, Swords RT, Thapa A, Thiel-Klare K, Traer E, Wagner J, Wilmot B, Wolf J, Wu G, Yates A, Zhang H, Cogle CR, Collins RH, Deininger MW, Hourigan CS, Jordan CT, Lin TL, Martinez ME, Pallapati RR, Pollyea DA, Pomicter AD, Watts JM, Weir SJ, Druker BJ, McWeeney SK, Tyner JW.
  Cancer Cell. 2022 Aug 08. 8(40).

• Lymphatics and fibroblasts support intestinal stem cells in homeostasis and injury.

  Goto N, Goto S, Imada S, Hosseini S, Deshpande V, Yilmaz ÖH.
  Cell Stem Cell. 2022 Aug 04. 8(29).

• Transcriptional profiles define drug refractory disease in myeloma.

  Zhu YX, Bruins LA, Chen X, Shi CX, Bonolo De Campos C, Meurice N, Wang X, Ahmann GJ, Ramsower CA, Braggio E, Rimsza LM, Stewart AK.
  EJHaem. 2022 Aug. 3(3).

• Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.

  Gosline SJC, Tognon C, Nestor M, Joshi S, Modak R, Damnernsawad A, Posso C, Moon J, Hansen JR, Hutchinson-Bunch C, Pino JC, Gritsenko MA, Weitz KK, Traer E, Tyner J, Druker B, Agarwal A, Piehowski P, McDermott JE, Rodland K.
  Clin Proteomics. 2022 Jul 27. 1(19).

• Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.

  Coleman IM, DeSarkar N, Morrissey C, Xin L, Roudier MP, Sayar E, Li D, Corey E, Haffner MC, Nelson PS.
  Clin Cancer Res. 2022 Jul 15. 14(28).

• Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.

  Rice WG, Howell SB, Zhang H, Rastgoo N, Local A, Kurtz SE, Lo P, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW.
  Mol Cancer Ther. 2022 Jul 05. 7(21).

• Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.

  Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG.
  J Clin Invest. 2022 Jul 01. 13(132).

• KRAS^G12C-independent feedback activation of wild-type RAS constrains KRAS^G12C inhibitor efficacy.

  Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, Kanikarla P, Gao F, Zhang Y, Zhou L, Kopetz S, Corcoran RB.
  Cell Rep. 2022 Jun 21. 12(39).

• Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup.

  Wiedmeier-Nutor JE, Bergsagel PL.
  Life (Basel). 2022 May 30. 6(12).

• Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.

  Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K, Bareja R, Han T, Liu EM, Palladino A, Di W, Gao D, Abida W, Beg S, Puca L, Meneses M, de Stanchina E, Berger MF, Gopalan A, Dow LE, Mosquera JM, Beltran H, Sternberg CN, Chi P, Scher HI, Sboner A, Chen Y, Khurana E.
  Science. 2022 May 27. 6596(376).

• Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution.

  Yang D, Jones MG, Naranjo S, Rideout WM, Min KHJ, Ho R, Wu W, Replogle JM, Page JL, Quinn JJ, Horns F, Qiu X, Chen MZ, Freed-Pastor WA, McGinnis CS, Patterson DM, Gartner ZJ, Chow ED, Bivona TG, Chan MM, Yosef N, Jacks T, Weissman JS.
  Cell. 2022 May 26. 11(185).

• Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.

  Kurtz SE, Eide CA, Kaempf A, Long N, Bottomly D, Nikolova O, Druker BJ, McWeeney SK, Chang BH, Tyner JW, Agarwal A.
  Blood Adv. 2022 May 24. 10(6).

• Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.

  Patel RA, Coleman I, Roudier MP, Konnick EQ, Hanratty B, Dumpit R, Lucas JM, Ang LS, Low JY, Tretiakova MS, Ha G, Lee JK, True LD, De Marzo AM, Nelson PS, Morrissey C, Pritchard CC, Haffner MC.
  Cancer Res Commun. 2022 May. 5(2).

• Understanding Drug Sensitivity and Tackling Resistance in Cancer.

  Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD.
  Cancer Res. 2022 Apr 15. 8(82).

• Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis.

  Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, Kumar D, Caggiano EG, Capogiri M, Zhang B, Ji Y, Maity SN, Hu M, Bai S, Aparicio AM, Efstathiou E, Logothetis CJ, Navin N, Navone NM, Chen Y, Giancotti FG.
  Cell Rep. 2022 Apr 05. 1(39).
  
  Clinical Trial

• Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.

  Jiang H, Muir RK, Gonciarz RL, Olshen AB, Yeh I, Hann BC, Zhao N, Wang YH, Behr SC, Korkola JE, Evans MJ, Collisson EA, Renslo AR.
  J Exp Med. 2022 Apr 04. 4(219).

• ETS factors in prostate cancer.

  Qian C, Li D, Chen Y.
  Cancer Lett. 2022 Apr 01. (530).

• Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.

  Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, Bivona TG, Wood KC.
  Sci Transl Med. 2022 Mar 30. 638(14).

• Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.

  Thieme E, Liu T, Bruss N, Roleder C, Lam V, Wang X, Nechiporuk T, Shouse G, Danilova OV, Bottomly D, McWeeney SK, Tyner JW, Kurtz SE, Danilov AV.
  Cell Death Dis. 2022 Mar 16. 3(13).

• secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.

  Kumar H, Mazumder S, Chakravarti S, Sharma N, Mukherjee UK, Kumar S, Baughn LB, Van Ness BG, Mitra AK.
  Blood Cancer J. 2022 Mar 09. 3(12).

• Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.

  Manabe T, Bivona TG.
  J Clin Invest. 2022 Feb 15. 4(132).

• Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.

  Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N.
  Cell Rep Med. 2022 Feb 15. 2(3).

• Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer.

  Siravegna G, O'Boyle CJ, Varmeh S, Queenan N, Michel A, Stein J, Thierauf J, Sadow PM, Faquin WC, Perry SK, Bard AZ, Wang W, Deschler DG, Emerick KS, Varvares MA, Park JC, Clark JR, Chan AW, Andreu Arasa VC, Sakai O, Lennerz J, Corcoran RB, Wirth LJ, Lin DT, Iafrate AJ, Richmon JD, Faden DL.
  Clin Cancer Res. 2022 Feb 15. 4(28).

• Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.

  Jiang H, Courau T, Borison J, Ritchie AJ, Mayer AT, Krummel MF, Collisson EA.
  Gastroenterology. 2022 Feb. 2(162).

• Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.

  Damnernsawad A, Bottomly D, Kurtz SE, Eide CA, McWeeney SK, Tyner JW, Nechiporuk T.
  Haematologica. 2022 Jan 01. 1(107).

• Plasma-only ctDNA-Guided MRD Detection in Patients with CRC-Response.

  Parikh AR, Corcoran RB.
  Clin Cancer Res. 2021 Dec 01. 23(27).

• CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.

  Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ.
  Cell Rep. 2021 Nov 30. 9(37).

• Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids.

  Barbosa Rabago D, Blakely CM, Haderk F, Bivona TG.
  J Vis Exp. 2021 Nov 22. 177().

• FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.

  Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM.
  Cancer Discov. 2021 Oct. 10(11).

• A novel activating JAK1 mutation in chronic eosinophilic leukemia.

  Shomali W, Damnernsawad A, Theparee T, Sampson D, Morrow Q, Yang F, Fernandez-Pol S, Press R, Zehnder J, Tyner JW, Gotlib J.
  Blood Adv. 2021 Sep 28. 18(5).

• Spatially organized multicellular immune hubs in human colorectal cancer.

  Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, Bejnood A, Dionne D, Ge WH, Xu KH, Chao SX, Zollinger DR, Lieb DJ, Reeves JW, Fuhrman CA, Hoang ML, Delorey T, Nguyen LT, Waldman J, Klapholz M, Wakiro I, Cohen O, Albers J, Smillie CS, Cuoco MS, Wu J, Su MJ, Yeung J, Vijaykumar B, Magnuson AM, Asinovski N, Moll T, Goder-Reiser MN, Applebaum AS, Brais LK, DelloStritto LK, Denning SL, Phillips ST, Hill EK, Meehan JK, Frederick DT, Sharova T, Kanodia A, Todres EZ, Jané-Valbuena J, Biton M, Izar B, Lambden CD, Clancy TE, Bleday R, Melnitchouk N, Irani J, Kunitake H, Berger DL, Srivastava A, Hornick JL, Ogino S, Rotem A, Vigneau S, Johnson BE, Corcoran RB, Sharpe AH, Kuchroo VK, Ng K, Giannakis M, Nieman LT, Boland GM, Aguirre AJ, Anderson AC, Rozenblatt-Rosen O, Regev A, Hacohen N.
  Cell. 2021 Sep 02. 18(184).

• BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.

  Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ.
  Clin Cancer Res. 2021 Sep 01. 17(27).
  
  Data

• Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.

  Romine KA, Nechiporuk T, Bottomly D, Jeng S, McWeeney SK, Kaempf A, Corces MR, Majeti R, Tyner JW.
  Blood Cancer Discov. 2021 Sep. 5(2).

• Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.

  Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, Hsieh AC, Chen Y, Carver BS.
  Nat Commun. 2021 Aug 20. 1(12).
  
  Data

• Rapid interrogation of cancer cell of origin through CRISPR editing.

  Feng W, Cao Z, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Rivera AA, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, Jasin M, Sawyers CL.
  Proc Natl Acad Sci U S A. 2021 Aug 10. 32(118).

• Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.

  Zaman A, Wu X, Lemoff A, Yadavalli S, Lee J, Wang C, Cooper J, McMillan EA, Yeaman C, Mirzaei H, White MA, Bivona TG.
  Cell Rep. 2021 Aug 03. 5(36).
  
  Data

• Clinical Acquired Resistance to KRAS^G12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.

  Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB.
  Cancer Discov. 2021 Aug. 8(11).
  
  Clinical Trial

• The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.

  Labrecque MP, Alumkal JJ, Coleman IM, Nelson PS, Morrissey C.
  Endocr Relat Cancer. 2021 Jul 15. 8(28).

• The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.

  Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, Fillmore TL, Tsai CF, Schepmoes AA, Shi T, Arshad OA, McDermott JE, Babur O, Watanabe-Smith K, Demir E, D'Alessandro A, Liu T, Tognon CE, Tyner JW, McWeeney SK, Rodland KD, Druker BJ, Traer E.
  Cancer Cell. 2021 Jul 12. 7(39).
  
  Data Clinical Trial

• Stepwise evolution of therapy resistance in AML.

  Gui P, Bivona TG.
  Cancer Cell. 2021 Jul 12. 7(39).

• Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.

  Lim Y, Arora S, Schuster SL, Corey L, Fitzgibbon M, Wladyka CL, Wu X, Coleman IM, Delrow JJ, Corey E, True LD, Nelson PS, Ha G, Hsieh AC.
  Nat Commun. 2021 Jul 09. 1(12).
  
  Data Model

• A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.

  Joshi SK, Sharzehi S, Pittsenbarger J, Bottomly D, Tognon CE, McWeeney SK, Druker BJ, Traer E.
  Am J Hematol. 2021 Jul 01. 7(96).

• Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

  Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Bergsagel PL, Chesi M.
  Blood Cancer Discov. 2021 Jul. 4(2).
  
  Model

• Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.

  Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS.
  J Clin Invest. 2021 Jun 15. 12(131).

• High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity.

  Mana MD, Hussey AM, Tzouanas CN, Imada S, Barrera Millan Y, Bahceci D, Saiz DR, Webb AT, Lewis CA, Carmeliet P, Mihaylova MM, Shalek AK, Yilmaz ÖH.
  Cell Rep. 2021 Jun 08. 10(35).

• A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.

  Lo YH, Kolahi KS, Du Y, Chang CY, Krokhotin A, Nair A, Sobba WD, Karlsson K, Jones SJ, Longacre TA, Mah AT, Tercan B, Sockell A, Xu H, Seoane JA, Chen J, Shmulevich I, Weissman JS, Curtis C, Califano A, Fu H, Crabtree GR, Kuo CJ.
  Cancer Discov. 2021 Jun. 6(11).
  
  Data Model

• Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.

  Kerr DL, Haderk F, Bivona TG.
  Curr Opin Chem Biol. 2021 Jun. (62).

• Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities.

  Yin Q, Yu W, Grzeskowiak CL, Li J, Huang H, Guo J, Chen L, Wang F, Zhao F, von Boehmer L, Metzner TJ, Leppert JT, Chien YH, Kuo CJ, Davis MM.
  Proc Natl Acad Sci U S A. 2021 May 25. 21(118).

• Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.

  Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG.
  Cell. 2021 May 13. 10(184).

• DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.

  Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC.
  Genome Res. 2021 May. 5(31).
  
  Data

• Spatial decoding of endosomal cAMP signals by a metastable cytoplasmic PKA network.

  Peng GE, Pessino V, Huang B, von Zastrow M.
  Nat Chem Biol. 2021 May. 5(17).

• A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

  Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN, Heist RS.
  J Thorac Oncol. 2021 May. 5(16).
  
  Clinical Trial

• CRISPR-based functional genomics in human dendritic cells.

  Jost M, Jacobson AN, Hussmann JA, Cirolia G, Fischbach MA, Weissman JS.
  Elife. 2021 Apr 27. (10).

• Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.

  Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS.
  Nat Commun. 2021 Mar 03. 1(12).
  
  Data

• Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.

  Tognon CE, Sears RC, Mills GB, Gray JW, Tyner JW.
  Annu Rev Cancer Biol. 2021 Mar. (5).

• Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.

  Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS.
  Science. 2021 Feb 26. 6532(371).
  
  Data

• Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.

  Moses BS, McCullough S, Fox JM, Mott BT, Bentzen SM, Kim M, Tyner JW, Lapidus RG, Emadi A, Rudek MA, Kingsbury TJ, Civin CI.
  Blood Adv. 2021 Feb 09. 3(5).

• Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report.

  Carratt SA, Brewer D, Maxson JE, Druker BJ, Braun TP.
  Biomark Res. 2021 Jan 30. 1(9).

• Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.

  Dhimolea E, de Matos Simoes R, Kansara D, Weng X, Sharma S, Awate P, Liu Z, Gao D, Mitsiades N, Schwab JH, Chen Y, Jeselsohn R, Culhane AC, Brown M, Georgakoudi I, Mitsiades CS.
  Cancer Res. 2021 Jan 15. 2(81).

• Modeling human adaptive immune responses with tonsil organoids.

  Wagar LE, Salahudeen A, Constantz CM, Wendel BS, Lyons MM, Mallajosyula V, Jatt LP, Adamska JZ, Blum LK, Gupta N, Jackson KJL, Yang F, Röltgen K, Roskin KM, Blaine KM, Meister KD, Ahmad IN, Cortese M, Dora EG, Tucker SN, Sperling AI, Jain A, Davies DH, Felgner PL, Hammer GB, Kim PS, Robinson WH, Boyd SD, Kuo CJ, Davis MM.
  Nat Med. 2021 Jan. 1(27).
  
  Data

• Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.

  Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, Newman W, Sirard CA, Fleisher M, Morris MJ, Chen Y, Larson SM, Haffner MC, Nelson PS, Schultz N, Garabedian MJ, Scher HI, Logan SK, Sawyers CL.
  JCO Precis Oncol. 2020. (4).
  
  Clinical Trial

• Strategies for Measuring Induction of Fatty Acid Oxidation in Intestinal Stem and Progenitor Cells.

  Cheng CW, Yilmaz OH, Mihaylova MM.
  Methods Mol Biol. 2020. (2171).

• Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.

  Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK.
  Clin Cancer Res. 2020 Dec 15. 24(26).

• CloneSifter: enrichment of rare clones from heterogeneous cell populations.

  Feldman D, Tsai F, Garrity AJ, O'Rourke R, Brenan L, Ho P, Gonzalez E, Konermann S, Johannessen CM, Beroukhim R, Bandopadhayay P, Blainey PC.
  BMC Biol. 2020 Nov 24. 1(18).

• Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.

  Cyrta J, Augspach A, De Filippo MR, Prandi D, Thienger P, Benelli M, Cooley V, Bareja R, Wilkes D, Chae SS, Cavaliere P, Dephoure N, Uldry AC, Lagache SB, Roma L, Cohen S, Jaquet M, Brandt LP, Alshalalfa M, Puca L, Sboner A, Feng F, Wang S, Beltran H, Lotan T, Spahn M, Kruithof-de Julio M, Chen Y, Ballman KV, Demichelis F, Piscuoglio S, Rubin MA.
  Nat Commun. 2020 Nov 03. 1(11).
  
  Data

• ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.

  Li F, Yuan Q, Di W, Xia X, Liu Z, Mao N, Li L, Li C, He J, Li Y, Guo W, Zhang X, Zhu Y, Aji R, Wang S, Tong X, Ji H, Chi P, Carver B, Wang Y, Chen Y, Gao D.
  J Clin Invest. 2020 Nov 02. 11(130).

• Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.

  Chaudhary SP, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikh A, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, Roeland EJ, Goyal L, Allen J, Mullen JT, Ryan DP, Iafrate AJ, Klempner SJ, Clark JW, Hong TS.
  Oncologist. 2020 Nov. 11(25).

• ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.

  Joshi SK, Keck JM, Eide CA, Bottomly D, Traer E, Tyner JW, McWeeney SK, Tognon CE, Druker BJ.
  Leukemia. 2020 Oct. 10(34).

• Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.

  Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE.
  J Thorac Oncol. 2020 Oct. 10(15).

• Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.

  Shi CX, Zhu YX, Bruins LA, Bonolo de Campos C, Stewart W, Braggio E, Stewart AK.
  Mol Cancer Res. 2020 Oct. 10(18).

• Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.

  Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG.
  Cell. 2020 Sep 03. 5(182).
  
  Data Clinical Trial

• Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.

  Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Chang BH, Danilov AV, Tyner JW.
  Leukemia. 2020 Sep. 9(34).

• Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips.

  Guo W, Li L, He J, Liu Z, Han M, Li F, Xia X, Zhang X, Zhu Y, Wei Y, Li Y, Aji R, Dai H, Wei H, Li C, Chen Y, Chen L, Gao D.
  Nat Genet. 2020 Sep. 9(52).

• Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.

  Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL.
  Cancer Cell. 2020 Aug 10. 2(38).
  
  Data Model

• Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.

  Zhang H, Nakauchi Y, Köhnke T, Stafford M, Bottomly D, Thomas R, Wilmot B, McWeeney SK, Majeti R, Tyner JW.
  Nat Cancer. 2020 Aug. 8(1).
  
  Model

• Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma.

  Anderson AN, McClanahan D, Jacobs J, Jeng S, Vigoda M, Blucher AS, Zheng C, Yoo YJ, Hale C, Ouyang X, Clayburgh D, Andersen P, Tyner JW, Bar A, Lucero OM, Leitenberger JJ, McWeeney SK, Kulesz-Martin M.
  Cold Spring Harb Mol Case Stud. 2020 Aug. 4(6).

• Applications of Organoids for Cancer Biology and Precision Medicine.

  Lo YH, Karlsson K, Kuo CJ.
  Nat Cancer. 2020 Aug. 8(1).

• Organoid Models of Tumor Immunology.

  Yuki K, Cheng N, Nakano M, Kuo CJ.
  Trends Immunol. 2020 Aug. 8(41).

• In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma.

  Mitra AK, Kumar H, Ramakrishnan V, Chen L, Baughn L, Kumar S, Rajkumar SV, Van Ness BG.
  Blood Cancer J. 2020 Jul 28. 7(10).

• Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.

  Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, Schenk G, Shain AH, Biddle FG, Collisson E, Snyder M, Bivona TG.
  Nat Commun. 2020 Jul 22. 1(11).
  
  Data

• Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.

  Rosenberg MW, Watanabe-Smith K, Tyner JW, Tognon CE, Druker BJ, Borate U.
  Oncotarget. 2020 Jul 21. 29(11).

• Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis.

  Leibold J, Ruscetti M, Cao Z, Ho YJ, Baslan T, Zou M, Abida W, Feucht J, Han T, Barriga FM, Tsanov KM, Zamechek L, Kulick A, Amor C, Tian S, Rybczyk K, Salgado NR, Sánchez-Rivera FJ, Watson PA, de Stanchina E, Wilkinson JE, Dow LE, Abate-Shen C, Sawyers CL, Lowe SW.
  Cancer Discov. 2020 Jul. 7(10).
  
  Data Model

• Retinoic Acid and Lymphotoxin Signaling Promote Differentiation of Human Intestinal M Cells.

  Ding S, Song Y, Brulois KF, Pan J, Co JY, Ren L, Feng N, Yasukawa LL, Sánchez-Tacuba L, Wosen JE, Mellins ED, Monack DM, Amieva MR, Kuo CJ, Butcher EC, Greenberg HB.
  Gastroenterology. 2020 Jul. 1(159).

• Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression.

  Chesi M, Stein CK, Garbitt VM, Sharik ME, Asmann YW, Bergsagel M, Riggs DL, Welsh SJ, Meermeier EW, Kumar SK, Braggio E, Bergsagel PL.
  Blood Cancer Discov. 2020 Jul. 1(1).
  
  Data Model

• Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.

  Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M, Soong D, LeFave CV, Huang F, Adams H, Loriaux MM, Tognon CE, Lo P, Tyner JW, Fan G, McWeeney SK, Druker BJ, Lind EF.
  Proc Natl Acad Sci U S A. 2020 Jun 23. 25(117).

• Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.

  Braun TP, Coblentz C, Curtiss BM, Coleman DJ, Schonrock Z, Carratt SA, Callahan RL, Maniaci B, Druker BJ, Maxson JE.
  Proc Natl Acad Sci U S A. 2020 Jun 16. 24(117).
  
  Data Model

• Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.

  Joshi SK, Qian K, Bisson WH, Watanabe-Smith K, Huang A, Bottomly D, Traer E, Tyner JW, McWeeney SK, Davare MA, Druker BJ, Tognon CE.
  Blood. 2020 Jun 11. 24(135).

• Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.

  Stoner RC, Press RD, Maxson JE, Tyner JW, Dao KT.
  Leukemia. 2020 Jun. 6(34).

• Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance.

  Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Sen T, Rudin CM.
  Nat Rev Clin Oncol. 2020 Jun. 6(17).

• Lineage plasticity in cancer: a shared pathway of therapeutic resistance.

  Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Sen T, Rudin CM.
  Nat Rev Clin Oncol. 2020 Jun. 6(17).

• AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.

  Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, Røsland GV, Siraji MI, Hellesøy M, Rayford A, Jacobsen K, Ditzel HJ, Vintermyr OK, Bivona TG, Minna J, Brekken RA, Baguley B, Micklem D, Akslen LA, Gausdal G, Simonsen A, Thiery JP, Chouaib S, Lorens JB, Engelsen AST.
  J Thorac Oncol. 2020 Jun. 6(15).

• Identification of PIKfyve kinase as a target in multiple myeloma.

  de Campos CB, Zhu YX, Sepetov N, Romanov S, Bruins LA, Shi CX, Stein CK, Petit JL, Polito AN, Sharik ME, Meermeier EW, Ahmann GJ, Armenta IDL, Kruse J, Bergsagel PL, Chesi M, Meurice N, Braggio E, Stewart AK.
  Haematologica. 2020 Jun. 6(105).

• "Direct to Drug" screening as a precision medicine tool in multiple myeloma.

  Bonolo de Campos C, Meurice N, Petit JL, Polito AN, Zhu YX, Wang P, Bruins LA, Wang X, Lopez Armenta ID, Darvish SA, Ahmann GJ, Henderson KJ, Tian S, Kruse JJ, Stewart WM, Larsen JT, Reeder CB, Dingli D, Kapoor P, Kumar SK, Fonseca R, Bergsagel PL, Braggio E, Stewart AK.
  Blood Cancer J. 2020 May 11. 5(10).

• Regenerative potential of prostate luminal cells revealed by single-cell analysis.

  Karthaus WR, Hofree M, Choi D, Linton EL, Turkekul M, Bejnood A, Carver B, Gopalan A, Abida W, Laudone V, Biton M, Chaudhary O, Xu T, Masilionis I, Manova K, Mazutis L, Pe'er D, Regev A, Sawyers CL.
  Science. 2020 May 01. 6490(368).
  
  Data

• EGFR targeted therapy resistance: current status, challenges, and future outlook.

  Bivona TG.
  J Thorac Dis. 2020 May. 5(12).

• Region-Specific Proteome Changes of the Intestinal Epithelium during Aging and Dietary Restriction.

  Gebert N, Cheng CW, Kirkpatrick JM, Di Fraia D, Yun J, Schädel P, Pace S, Garside GB, Werz O, Rudolph KL, Jasper H, Yilmaz ÖH, Ori A.
  Cell Rep. 2020 Apr 28. 4(31).

• Betacellulin drives therapy resistance in glioblastoma.

  Fan Q, An Z, Wong RA, Luo X, Lu ED, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA.
  Neuro Oncol. 2020 Apr 15. 4(22).

• Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.

  Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio B, Goyal L, Nipp RD, Roeland E, Weekes CD, Wo JY, Zhu AX, Dias-Santagata D, Iafrate AJ, Lennerz JK, Hong TS, Siravegna G, Horick N, Clark JW, Corcoran RB.
  Clin Cancer Res. 2020 Apr 15. 8(26).

• Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.

  Wasmuth EV, Hoover EA, Antar A, Klinge S, Chen Y, Sawyers CL.
  Proc Natl Acad Sci U S A. 2020 Apr 14. 15(117).

• Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.

  Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P.
  Cancer Cell. 2020 Apr 13. 4(37).
  
  Data Model

• Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

  Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW.
  J Clin Oncol. 2020 Apr 01. 10(38).
  
  Clinical Trial

• Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.

  Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, Lee YS, Sullivan P, Zhang Z, Choi D, Rosen N, Sawyers CL, Gopalan A, Chen Y, Carver BS.
  Cancer Res. 2020 Apr 01. 7(80).
  
  Clinical Trial

• Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.

  Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown LG, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS.
  Clin Cancer Res. 2020 Apr 01. 7(26).
  
  Model

• Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS^G12C Inhibition.

  Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, Hong CB, Corcoran RB.
  Clin Cancer Res. 2020 Apr 01. 7(26).
  
  Model Clinical Trial

• Blockchain-Authenticated Sharing of Genomic and Clinical Outcomes Data of Patients With Cancer: A Prospective Cohort Study.

  Glicksberg BS, Burns S, Currie R, Griffin A, Wang ZJ, Haussler D, Goldstein T, Collisson E.
  J Med Internet Res. 2020 Mar 20. 3(22).

• NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2^V617F-positive myeloproliferative neoplasm cells.

  Fenerich BA, Fernandes JC, Rodrigues Alves APN, Coelho-Silva JL, Scopim-Ribeiro R, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado-Neto JA, Traina F.
  Signal Transduct Target Ther. 2020 Jan 24. 1(5).

• Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

  Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.
  Clin Cancer Res. 2020 Jan 15. 2(26).

• MYC dysregulation in the progression of multiple myeloma.

  Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortüm KM, Keats JJ, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL.
  Leukemia. 2020 Jan. 1(34).
  
  Clinical Trial

• Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz.

  Blucher AS, McWeeney SK, Stein L, Wu G.
  F1000Res. 2019. (8).

• Targeting the evolution of drug resistance in lung cancer.

  Shah KN, Bandyopadhyay S.
  Mol Cell Oncol. 2019. 5(6).

• Human Intestinal Enteroids Model MHC-II in the Gut Epithelium.

  Wosen JE, Ilstad-Minnihan A, Co JY, Jiang W, Mukhopadhyay D, Fernandez-Becker NQ, Kuo CJ, Amieva MR, Mellins ED.
  Front Immunol. 2019. (10).

• Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

  Digumarthy SR, Mendoza DP, Zhang EW, Lennerz JK, Heist RS.
  Cancers (Basel). 2019 Dec 17. 12(11).

• Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.

  Agarwal A, Bolosky WJ, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ.
  Proc Natl Acad Sci U S A. 2019 Dec 03. 49(116).

• The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.

  Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.
  Clin Cancer Res. 2019 Dec 01. 23(25).

• The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.

  Yan Y, Ma J, Wang D, Lin D, Pang X, Wang S, Zhao Y, Shi L, Xue H, Pan Y, Zhang J, Wahlestedt C, Giles FJ, Chen Y, Gleave ME, Collins CC, Ye D, Wang Y, Huang H.
  EMBO Mol Med. 2019 Nov 07. 11(11).

• Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.

  Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, Bhola PD, Ryan J, Guerriero JL, Montero J, Liang FJ, Cherniack AD, Piccioni F, Matulonis UA, Bowtell DDL, Sarosiek KA, Letai A, Garraway LA, Johannessen CM, Meyerson M.
  Mol Cancer Res. 2019 Nov. 11(17).

• Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses.

  Pappas KJ, Choi D, Sawyers CL, Karthaus WR.
  J Vis Exp. 2019 Oct 24. 152().

• Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.

  Moshofsky KB, Cho HJ, Wu G, Romine KA, Newman MT, Kosaka Y, McWeeney SK, Lind EF.
  Blood Adv. 2019 Oct 22. 20(3).
  
  Model

• A rectal cancer organoid platform to study individual responses to chemoradiation.

  Ganesh K, Wu C, O'Rourke KP, Szeglin BC, Zheng Y, Sauvé CG, Adileh M, Wasserman I, Marco MR, Kim AS, Shady M, Sanchez-Vega F, Karthaus WR, Won HH, Choi SH, Pelossof R, Barlas A, Ntiamoah P, Pappou E, Elghouayel A, Strong JS, Chen CT, Harris JW, Weiser MR, Nash GM, Guillem JG, Wei IH, Kolesnick RN, Veeraraghavan H, Ortiz EJ, Petkovska I, Cercek A, Manova-Todorova KO, Saltz LB, Lavery JA, DeMatteo RP, Massagué J, Paty PB, Yaeger R, Chen X, Patil S, Clevers H, Berger MF, Lowe SW, Shia J, Romesser PB, Dow LE, Garcia-Aguilar J, Sawyers CL, Smith JJ.
  Nat Med. 2019 Oct. 10(25).
  
  Data Model

• Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

  Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.
  Blood. 2019 Sep 12. 11(134).
  
  Data

• MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer.

  Venkateswaran N, Lafita-Navarro MC, Hao YH, Kilgore JA, Perez-Castro L, Braverman J, Borenstein-Auerbach N, Kim M, Lesner NP, Mishra P, Brabletz T, Shay JW, DeBerardinis RJ, Williams NS, Yilmaz OH, Conacci-Sorrell M.
  Genes Dev. 2019 Sep 01. 17-18(33).

• Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.

  Mao N, Gao D, Hu W, Hieronymus H, Wang S, Lee YS, Lee C, Choi D, Gopalan A, Chen Y, Carver BS.
  Mol Cancer Ther. 2019 Sep. 9(18).
  
  Data Model Clinical Trial

• Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.

  Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB.
  Nat Med. 2019 Sep. 9(25).
  
  Data

• Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

  Bai X, Fisher DE, Flaherty KT.
  Nat Rev Clin Oncol. 2019 Sep. 9(16).

• Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

  Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG.
  Cell Rep. 2019 Aug 27. 9(28).
  
  Data Model

• Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet.

  Cheng CW, Biton M, Haber AL, Gunduz N, Eng G, Gaynor LT, Tripathi S, Calibasi-Kocal G, Rickelt S, Butty VL, Moreno-Serrano M, Iqbal AM, Bauer-Rowe KE, Imada S, Ulutas MS, Mylonas C, Whary MT, Levine SS, Basbinar Y, Hynes RO, Mino-Kenudson M, Deshpande V, Boyer LA, Fox JG, Terranova C, Rai K, Piwnica-Worms H, Mihaylova MM, Regev A, Yilmaz ÖH.
  Cell. 2019 Aug 22. 5(178).

• Targeting Oncogenic BRAF: Past, Present, and Future.

  Zaman A, Wu W, Bivona TG.
  Cancers (Basel). 2019 Aug 16. 8(11).

• TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

  Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.
  Cancer Discov. 2019 Aug. 8(9).

• The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

  Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC.
  Sci Transl Med. 2019 Jul 31. 503(11).
  
  Model

• CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.

  Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG.
  J Clin Invest. 2019 Jul 22. 8(129).

• The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

  Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW.
  Cancer Discov. 2019 Jul. 7(9).
  
  Data

• FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.

  Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL.
  Nature. 2019 Jul. 7765(571).
  
  Data Model

• Genomic correlates of clinical outcome in advanced prostate cancer.

  Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.
  Proc Natl Acad Sci U S A. 2019 Jun 04. 23(116).
  
  Data

• Engineering Multidimensional Evolutionary Forces to Combat Cancer.

  McCoach CE, Bivona TG.
  Cancer Discov. 2019 May. 5(9).

• Next-generation characterization of the Cancer Cell Line Encyclopedia.

  Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR.
  Nature. 2019 May. 7757(569).

• Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

  Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.
  JAMA Oncol. 2019 Apr 01. 4(5).

• Dampening oncogenic RAS signaling.

  Bivona TG.
  Science. 2019 Mar 22. 6433(363).

• Strategies to Identify and Target Cells of Origin in Prostate Cancer.

  Karthaus WR, Sawyers CL.
  J Natl Cancer Inst. 2019 Mar 01. 3(111).

• Polytherapy and Targeted Cancer Drug Resistance.

  Chatterjee N, Bivona TG.
  Trends Cancer. 2019 Mar. 3(5).

• Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.

  Sabnis AJ, Bivona TG.
  Trends Mol Med. 2019 Mar. 3(25).

• Targeting Alterations in the RAF-MEK Pathway.

  Yaeger R, Corcoran RB.
  Cancer Discov. 2019 Mar. 3(9).

• CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

  Edwards DK, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, McWeeney SK, Tyner JW.
  Blood. 2019 Feb 07. 6(133).

• FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.

  Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.
  Elife. 2019 Feb 05. (8).
  
  Model

• Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

  Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG.
  Cancer Res. 2019 Feb 01. 3(79).
  
  Model

• Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

  Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.
  Leuk Res. 2019 Feb. (77).

• Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy.

  Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM.
  Nat Cell Biol. 2019 Feb. 2(21).
  
  Data

• Mechanisms of Resistance to Immune Checkpoint Blockade.

  Liu D, Jenkins RW, Sullivan RJ.
  Am J Clin Dermatol. 2019 Feb. 1(20).

• Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

  Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.
  Nat Commun. 2019 Jan 16. 1(10).
  
  Data Clinical Trial

• GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance.

  Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL.
  Elife. 2019 Jan 15. (8).
  
  Data Model

• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

  Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.
  Cell. 2019 Jan 10. 1-2(176).

• Molecular signatures of multiple myeloma progression through single cell RNA-Seq.

  Jang JS, Li Y, Mitra AK, Bi L, Abyzov A, van Wijnen AJ, Baughn LB, Van Ness B, Rajkumar V, Kumar S, Jen J.
  Blood Cancer J. 2019 Jan 03. 1(9).

• Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

  Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S.
  Nat Med. 2019 Jan. 1(25).
  
  Clinical Trial

• Automation of ReactomeFIViz via CyREST API.

  Loney F, Wu G.
  F1000Res. 2018. (7).

• Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.

  Lamble AJ, Lind EF.
  Front Oncol. 2018. (8).

• A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.

  Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE.
  Cancer Res. 2018 Dec 15. 24(78).

• Organoid Modeling of the Tumor Immune Microenvironment.

  Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ.
  Cell. 2018 Dec 13. 7(175).
  
  Data Model

• Two myeloid leukemia cases with rare FLT3 fusions.

  Zhang H, Paliga A, Hobbs E, Moore S, Olson S, Long N, Dao KT, Tyner JW.
  Cold Spring Harb Mol Case Stud. 2018 Dec. 6(4).

• T Helper Cell Cytokines Modulate Intestinal Stem Cell Renewal and Differentiation.

  Biton M, Haber AL, Rogel N, Burgin G, Beyaz S, Schnell A, Ashenberg O, Su CW, Smillie C, Shekhar K, Chen Z, Wu C, Ordovas-Montanes J, Alvarez D, Herbst RH, Zhang M, Tirosh I, Dionne D, Nguyen LT, Xifaras ME, Shalek AK, von Andrian UH, Graham DB, Rozenblatt-Rosen O, Shi HN, Kuchroo V, Yilmaz OH, Regev A, Xavier RJ.
  Cell. 2018 Nov 15. 5(175).

• Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

  Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.
  J Clin Invest. 2018 Nov 01. 11(128).

• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

  Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.
  Cell. 2018 Nov 01. 4(175).
  
  Data Clinical Trial

• Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

  Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A.
  Leukemia. 2018 Nov. 11(32).

• Therapeutic strategies to target RAS-mutant cancers.

  Ryan MB, Corcoran RB.
  Nat Rev Clin Oncol. 2018 Nov. 11(15).

• Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

  Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.
  J Clin Invest. 2018 Oct 01. 10(128).

• Functional genomic landscape of acute myeloid leukaemia.

  Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.
  Nature. 2018 Oct. 7728(562).
  
  Data Clinical Trial

• Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast.

  Siravegna G, Corcoran RB.
  Cancer Discov. 2018 Oct. 10(8).

• TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.

  Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H.
  Clin Cancer Res. 2018 Sep 15. 18(24).
  
  Data

• Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

  Singer JW, Fleischman A, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A.
  Oncotarget. 2018 Sep 07. 70(9).

• Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

  Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.
  Elife. 2018 Sep 04. (7).

• Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

  Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.
  Leukemia. 2018 Sep. 9(32).
  
  Clinical Trial

• RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

  Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG.
  Nat Cell Biol. 2018 Sep. 9(20).
  
  Model Clinical Trial

• Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

  Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK.
  Haematologica. 2018 Aug. 8(103).

• Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

  Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW.
  Sci Signal. 2018 Jul 17. 539(11).

• Patient derived organoids to model rare prostate cancer phenotypes.

  Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.
  Nat Commun. 2018 Jun 19. 1(9).
  
  Data Model

• Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.

  Chen Y, Chi P.
  J Hematol Oncol. 2018 Jun 07. 1(11).

• TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

  Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA.
  J Clin Invest. 2018 Jun 01. 6(128).

• Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

  Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.
  Oncotarget. 2018 May 15. 37(9).

• A Convergence-Based Framework for Cancer Drug Resistance.

  Konieczkowski DJ, Johannessen CM, Garraway LA.
  Cancer Cell. 2018 May 14. 5(33).

• Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

  Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW.
  J Biol Chem. 2018 May 11. 19(293).

• Fasting Activates Fatty Acid Oxidation to Enhance Intestinal Stem Cell Function during Homeostasis and Aging.

  Mihaylova MM, Cheng CW, Cao AQ, Tripathi S, Mana MD, Bauer-Rowe KE, Abu-Remaileh M, Clavain L, Erdemir A, Lewis CA, Freinkman E, Dickey AS, La Spada AR, Huang Y, Bell GW, Deshpande V, Carmeliet P, Katajisto P, Sabatini DM, Yilmaz ÖH.
  Cell Stem Cell. 2018 May 03. 5(22).

• The long tail of oncogenic drivers in prostate cancer.

  Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM, Schultz N, Van Allen EM.
  Nat Genet. 2018 May. 5(50).

• Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

  Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.
  Eur Urol. 2018 May. 5(73).

• Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

  Zaman A, Bivona TG.
  Ann Transl Med. 2018 May. 9(6).

• COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.

  Xie Y, Cao Z, Wong EW, Guan Y, Ma W, Zhang JQ, Walczak EG, Murphy D, Ran L, Sirota I, Wang S, Shukla S, Gao D, Knott SR, Chang K, Leu J, Wongvipat J, Antonescu CR, Hannon G, Chi P, Chen Y.
  J Clin Invest. 2018 Apr 02. 4(128).

• Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.

  Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H.
  EMBO Mol Med. 2018 Apr. 4(10).

• Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF^V600E Colorectal Cancer.

  Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.
  Cancer Discov. 2018 Apr. 4(8).
  
  Data Model

• Challenges in validating candidate therapeutic targets in cancer.

  Settleman J, Sawyers CL, Hunter T.
  Elife. 2018 Feb 08. (7).

• Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.

  Lamble AJ, Dietz M, Laderas T, McWeeney S, Lind EF.
  J Immunol Methods. 2018 Feb. (453).

• Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

  Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.
  Cancer Discov. 2018 Feb. 2(8).

• Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.

  Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y, Li D, Wong EWP, Sboner A, Beltran H, Mosquera JM, Sher J, Cao Z, Wongvipat J, Koche RP, Gopalan A, Zheng D, Rubin MA, Scher HI, Chi P, Chen Y.
  Cancer Cell. 2017 Dec 11. 6(32).

• Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

  Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.
  Nat Genet. 2017 Dec. 12(49).
  
  Data

• Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

  Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.
  Cancer Cell. 2017 Oct 09. 4(32).
  
  Clinical Trial

• Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

  Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H.
  Nat Med. 2017 Sep. 9(23).

• Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

  Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W.
  Nat Med. 2017 Sep. 9(23).